Foghorn and Lilly halt FHD-909 program, company cuts 40% of workforce
Foghorn Therapeutics said it will not advance FHD-909 with Eli Lilly into expansion after Phase 1 data, and is reducing staff to focus on its own pipeline.
SEC filing
Latest
2 stories
Today
Thursday, August 6
Foghorn reports Q2 2026 results, FHD-909 trial on track with Lilly
Foghorn Therapeutics posted narrower Q2 losses and $167.6 million in cash as its lead SMARCA2 inhibitor advances in Phase 1 dose escalation for NSCLC.
SEC filing